Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $12.12 USD
Change Today +0.20 / 1.68%
Volume 1.2M
As of 8:10 PM 05/4/15 All times are local (Market data is delayed by at least 15 minutes).

merrimack pharmaceuticals in (MACK) Snapshot

Open
$12.09
Previous Close
$11.92
Day High
$12.70
Day Low
$11.85
52 Week High
04/27/15 - $13.84
52 Week Low
07/28/14 - $5.53
Market Cap
1.3B
Average Volume 10 Days
1.5M
EPS TTM
$-0.80
Shares Outstanding
107.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MERRIMACK PHARMACEUTICALS IN (MACK)

merrimack pharmaceuticals in (MACK) Related Bloomberg News

View More Bloomberg News

merrimack pharmaceuticals in (MACK) Related Businessweek News

No Related Businessweek News Found

merrimack pharmaceuticals in (MACK) Details

Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and preparing to commercialize medicines paired with companion diagnostics for the treatment of cancer primarily in the United States. Its therapeutic oncology candidates in clinical development include MM-398, a nanotherapeutic encapsulation of the chemotherapy drug irinotecan, which is has completed Phase III clinical trials for the treatment of patients with metastatic pancreatic cancer whose cancer had progressed on treatment with the chemotherapy drug gemcitabine; in a Phase I clinical trial as a monotherapy in patients with glioma and in combination with cyclophosphamide in patients with pediatric solid tumors; and in a Phase 1 translational clinical trial designed to identify predictive biomarkers associated with MM-398. The company’s therapeutic oncology candidates also include MM-302 that is in Phase II clinical trial for the treatment of patients with ErbB2 (HER2)-positive, locally advanced or metastatic breast cancer; MM-121, which is in Phase II clinical trial for the treatment of patients with heregulin positive, advanced non-small cell lung cancer, as well as ovarian, breast, and non-small cell lung cancers; and MM-111 that is in a Phase II clinical trial for the treatment of patients with advanced gastric, esophageal, and gastroesophageal junction cancers. In addition, its therapeutic oncology candidates consist of MM-151 and MM-141, which are in Phase I clinical trials for the treatment of patients with solid tumors. The company has collaboration and license agreements with Baxter International Inc., Baxter Healthcare Corporation, Baxter Healthcare SA, Actavis, Sanofi, PharmaEngine, Inc., Dyax Corp., Adimab LLC, and University of California. Merrimack Pharmaceuticals, Inc. was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

306 Employees
Last Reported Date: 02/27/15
Founded in 1993

merrimack pharmaceuticals in (MACK) Top Compensated Officers

Chief Executive Officer, President, Executive...
Total Annual Compensation: $527.3K
Chief Financial Officer and Treasurer
Total Annual Compensation: $293.9K
Senior Vice President of Corporate Operations
Total Annual Compensation: $351.7K
Head of Commercial and President of Merrimack...
Total Annual Compensation: $305.7K
Senior Vice President of Development
Total Annual Compensation: $273.2K
Compensation as of Fiscal Year 2014.

merrimack pharmaceuticals in (MACK) Key Developments

Merrimack Pharmaceuticals and Baxter Announces Completion of New Drug Application Submission to U.S. FDA for MM-398 as Treatment for Post-Gemcitabine Metastatic Pancreatic Cancer

Merrimack Pharmaceuticals, Inc. and Baxter International Inc. jointly announced that Merrimack has completed the rolling submission of the New Drug Application (NDA) for MM-398 (irinotecan liposome injection), also known as "nal-IRI," to the U.S. Food and Drug Administration (FDA). Merrimack is seeking U.S. marketing approval of MM-398 for the treatment of patients with metastatic adenocarcinoma of the pancreas who have been previously treated with gemcitabine-based therapy. The companies also announced that Merrimack has requested priority review of the MM-398 NDA by the FDA. Merrimack's application is based upon the results of an international Phase 3 study (NAPOLI-1) conducted in patients with metastatic pancreatic cancer who previously received gemcitabine-based therapy. MM-398 in combination with 5-fluorouracil (5-FU) and leucovorin achieved its primary and secondary endpoints by demonstrating a statistically significant improvement in overall survival, progression free survival and overall response rate compared to the control group of patients who received a combination of 5-FU and leucovorin. The most common Grade 3 or higher adverse events in patients receiving MM-398 and 5-FU/LV were neutropenia, fatigue and gastrointestinal effects. This was the first global Phase 3 study in a post-gemcitabine setting to show a survival benefit in this aggressive disease. The data were previously presented in June 2014.

Merrimack Pharmaceuticals, Inc. Announces Updated Clinical Data from A Multi-Arm Phase 1 Study of Mm-141

Merrimack Pharmaceuticals, Inc. announced updated clinical data from a multi-arm Phase 1 study of MM-141, a bispecific antibody targeting IGF-1R and ErbB3. The data were presented in an oral session by Dr. Mansoor Saleh, MD at the 2015 American Association for Cancer Research Annual Meeting in Philadelphia, PA. The trial evaluated the safety and tolerability of MM-141 as a monotherapy and in combination with everolimus or with nab-paclitaxel and gemcitabine in patients with advanced solid tumors. MM-141 is a novel bispecific tetravalent antibody that binds IGF-1R and ErbB3, which are receptors on the surface of tumor cells that can drive tumor growth and that are commonly co-expressed in solid tumors. Updated results from this Phase 1 trial show an acceptable safety profile for MM-141 as both a monotherapy and in combination with standard-of-care therapies. The most common adverse events in the study, of any grade, were nausea (50%), headache (47.4%), and vomiting (44.7%). Based on a retrospective analysis, patients treated at therapeutic dose levels (=20mg/kg of MM-141 either weekly or every other week) of MM-141 who had detectable levels of serum biomarker, free IGF-1, stayed on study for 3.2 cycles versus 1.8 cycles for patients whose free IGF-1 was not detectable. Data from the Phase 1 study were used to inform the design of the upcoming front-line Phase 2 study of MM-141. The planned Phase 2 study will examine MM-141 in combination with nab-paclitaxel and gemcitabine in patients with metastatic pancreatic cancer who have high serum levels of free IGF-1. The study is scheduled to begin in the first half of 2015. The U.S. Food and Drug Administration (FDA) has granted orphan drug designation for MM-141 for the treatment of pancreatic cancer. This orphan drug designation will potentially provide Merrimack with seven-year marketing exclusivity for MM-141 and other benefits if the drug is approved by the FDA.

Merrimack Announces Final Clinical Results for MM-302 Phase 1 Study Demonstrating Robust Activity in Heavily Pre-Treated Patients with HER2-Positive Metastatic Breast Cancer

Merrimack Pharmaceuticals, Inc. announced updated and final clinical results for the Phase 1 study of MM-302, a novel HER2-targeted liposomal doxorubicin, in HER2-positive metastatic breast cancer. Data described the safety and promising clinical activity of MM-302 in patients with advanced HER2-positive metastatic breast cancer. Results from the trial showed that the group of patients (n=62) treated with 30 mg/m2 or more of MM-302 alone, in combination with trastuzumab or with trastuzumab and cyclophosphamide, had a median progression free survival (mPFS) of 7.6 months (95% CI: 3.6-10.9 months) and an overall response rate (ORR) of 11%. Of note, 25 patients who had not been previously treated with anthracyclines had an mPFS of 11 months (95% CI: 1.8-13.1 months) and an ORR of 24%. The most frequent adverse events occurring in greater than 20% of the population in this Phase 1 study were constipation, cough, decreased appetite, diarrhea, dyspnea, fatigue, nausea, neutropenia, stomatitis and vomiting. The most common Grade 3/4 adverse event was neutropenia observed in 8 patients. Six out of 69 patients (9%) had protocol-defined asymptomatic declines in left ventricular ejection fraction (LVEF). In 1 of the 6 patients, this was reported as a Grade 1 cardiac failure that was possibly related to study treatment.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MACK:US $12.12 USD +0.20

MACK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for MACK.
View Industry Companies
 

Industry Analysis

MACK

Industry Average

Valuation MACK Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MERRIMACK PHARMACEUTICALS IN, please visit www.merrimackpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.